4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
RenovoRx, Inc. (RNXT) operates in the Biotechnology industry and is headquartered in Mountain View, United States with about 17 employees. Its market capitalization is roughly $39 million. In the fiscal year ended 2025-12-31, RNXT reported $1M in revenue and ($11M) in net income.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Interactive charts & full statements → Open the RNXT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M | — |
| Gross Profit | $1M | $0M | $0M | — | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($11M) | ($10M) | — |
| Net Income | ($11M) | ($9M) | ($10M) | ($10M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($4M) | ($4M) | ($3M) | ($3M) | ($3M) |
| Net Income | ($4M) | ($3M) | ($3M) | ($3M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $8M | $8M | $2M | $7M | — |
| Total Liabilities | $3M | $4M | $4M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RNXT viewer.
About TickerBase · Data methodology & sources